home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.14 -0.58 (-2.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Beam Therapeutics: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

May 10, 2023

From Beam Therapeutics

Via GlobeNewswire

7 Best Cathie Wood Stocks for Your May 2023 Buy List ↗

May 02, 2023

This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent.

Via InvestorPlace

3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers ↗

May 02, 2023

Cathie Wood is loading up on these biotech stocks.

Via The Motley Fool

The 3 Most Promising Gene Editing Stocks to Buy in 2023 ↗

April 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

Via InvestorPlace

Where Beam Therapeutics Stands With Analysts ↗

March 21, 2023

Via Benzinga

Where Beam Therapeutics Stands With Analysts ↗

March 01, 2023

Via Benzinga

Analyst Ratings for Beam Therapeutics ↗

February 01, 2023

Via Benzinga

Cathie Wood Is Unstoppable With Tesla Stock – Defies Wall Street To Make Whopping $29M Purchase ↗

April 26, 2023

Via Benzinga

3 Stocks to Watch in April: Is it Time to Buy? ↗

April 18, 2023

With several fundamental factors pushing against the equities sector, these stocks to watch in particular draw significant intrigue.

Via InvestorPlace

7 Top Growth Stocks to Buy for the Next Decade ↗

April 18, 2023

These Growth Stocks to Buy Don't Require a 10-year Horizon But Should be More Valuable Then

Via InvestorPlace

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global ↗

April 06, 2023

Via Benzinga

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗

March 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Via InvestorPlace

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

March 27, 2023

From Beam Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

March 21, 2023

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

March 15, 2023

From Beam Therapeutics

Via GlobeNewswire

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing ↗

March 06, 2023

CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on.

Via InvestorPlace

3 Game-Changing Stocks to Buy in March ↗

March 04, 2023

Innovation is in these companies' DNA.

Via The Motley Fool

The Top 7 Growth Stocks in Biotech ↗

March 03, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

Via InvestorPlace

Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference

March 01, 2023

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

February 28, 2023

From Beam Therapeutics

Via GlobeNewswire

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

February 07, 2023

From Beam Therapeutics

Via GlobeNewswire

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗

February 06, 2023

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

5 Top Stocks for February ↗

January 29, 2023

These growth stocks have more room to run.

Via The Motley Fool

3 Great Growth Stocks Down 20% or More to Buy Now ↗

January 27, 2023

These beaten-down stocks could be poised for major rebounds.

Via The Motley Fool

A New Bull Market Is Coming: 3 Stocks That Could Skyrocket ↗

January 21, 2023

Aggressive investors should check out these stocks.

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com